U.S., March 20 -- ClinicalTrials.gov registry received information related to the study (NCT07482540) titled 'Role of Dexmedatomidine Drug in Prevention of Atrial Fibrillations Post Mitral Valve Surgery' on March 14.
Brief Summary: Recently, dexmedetomidine has been suggested as an alternative agent for sedation in tachyarrhythmias due to its antiarrhythmic properties through decreased catecholamine release, prolonged refractory period, and increased vagal tone. In addition, dexmedetomidine is a highly selective agonist that does not interact with the gamma-aminobutyric acid (GABA) receptors. Thus, its analgesic properties are opioid sparing, which is unique among traditional ICU sedatives and avoids the issue of respiratory depression wit...